Penn Transplant Biobank and Registry (BioTIP)
Investigator: Kim Olthoff, MD
The purpose of the study is to see if substances in the donor organ can predict how well the organ will function after transplant. Tests on blood, urine and biopsy tissue samples will be used in this study to see if such a link exists. Patients who are expected to receive other organs (kidney, lung and heart) will also be part of this study. The research team will be looking at any injuries in the transplanted organs to see if there are similarities among the different organ groups. In this way, they hope to develop a better understanding of organ injury after transplant. Study participation lasts for the lifetime of the participant.
Research Coordinator: Lexi Tumblety
Phone: 267-441-1800
Email: Lexi.Tumblety@pennmedicine.upenn.edu
Liver Transplantation from Normothermic Perfusion (NRMP)
Investigator: Peter Abt, MD
The research study is being conducted to evaluate the outcomes of liver transplantation from deceased organ donors who undergo normothermic regional machine perfusion after cardiac death (DCD). The perfusion machine restores oxygenated blood flow to organs in the abdomen such as the liver. This type of perfusion machine is currently used in patients whose lungs cannot provide enough oxygen to the body. The use of the machine may improve the quality of the organs to be transplanted. It also allows the ability to assess organ function before transplantation potentially leading to superior outcomes compared to current DCD results. Participation is expected to last for one (1) year from time of transplant.
Research Coordinator: Lexi Tumblety
Phone: 267-441-1800
Email: Lexi.Tumblety@pennmedicine.upenn.edu
OrganOx Post-Approval Study
Investigator: Peter Abt, MD
The purpose of this study is to gather additional data on the use of the OrganOx metra device and to determine if the device provides improved outcomes in liver transplantation. Participation involves agreement to accepting a liver which has been transported using the FDA approved device as opposed to the cold storage transportation. Outcomes will be gathered by taking measurements of the function of the liver both during storage and after the liver has been transplanted. Participation is expected to last for one (1) year from time of transplant.
Research Coordinator: Lexi Tumblety
Phone: 267-441-1800
Email: Lexi.Tumblety@pennmedicine.upenn.edu
A randomized study to evaluate antibody response to an additional dose of SARS-CoV-2 vaccination with and without immunosuppression reduction in kidney and liver transplant recipients
Principal Investigator: Emily Blumberg, MD
The purpose of this study is to help us learn whether an additional dose of COVID-19 study vaccine with or without lowering an anti-rejection medicine can help transplant recipients make more antibody to COVID-19. This study will enroll kidney or liver recipients at least 12 months post-transplant who have received 2-4 doses of the Moderna or Pfizer COVID-19 vaccine at least 30 days ago.
Sponsor: NIH
Research Coordinator: Maryann Najdzinowicz, Clinical Research Nurse
Email: Maryann.Najdzinowicz@pennmedicine.upenn.edu
Phone: 215-662-4007
HOPE in Action Prospective Multicenter, Clinical Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients
Principal Investigator: Emily Blumberg, MD
The purpose of this study is to determine if an HIV+ donor liver transplant is safe with regards to major transplant-related and HIV-related complications
Sponsor: NIH
Research Coordinator: Maryann Najdzinowicz, Clinical Research Nurse
Email: Maryann.Najdzinowicz@pennmedicine.upenn.edu
Phone: 215-662-4007